The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

AstraZeneca logo

AstraZeneca

Status and phase

Completed
Phase 1

Conditions

Schizophrenia

Treatments

Drug: AZD8529
Drug: Placebo to match AZD8529

Study type

Interventional

Funder types

Industry

Identifiers

NCT00986531
D2285M00016

Details and patient eligibility

About

The purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.

Enrollment

59 patients

Sex

All

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

DSM-IV diagnosis of schizophrenia or schizoaffective disorder

Exclusion criteria

  • ECT in the last 6 months
  • Substance abuse or dependence
  • History of claustrophobia

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

59 participants in 2 patient groups, including a placebo group

1
Experimental group
Description:
80 mg AZD8529
Treatment:
Drug: AZD8529
2
Placebo Comparator group
Description:
Placebo
Treatment:
Drug: Placebo to match AZD8529

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems